Global Pet Cancer Therapeutics Market – Industry Trends and Forecast to 2031

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

Global Pet Cancer Therapeutics Market – Industry Trends and Forecast to 2031

  • Healthcare
  • Upcoming Report
  • Jul 2024
  • Global
  • 350 Pages
  • 테이블 수: 220
  • 그림 수: 60

Global Pet Cancer Therapeutics Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2024 –2031
Diagram 시장 규모(기준 연도)
USD 283.86 Million
Diagram 시장 규모(예측 연도)
USD 569.77 Million
Diagram 연평균 성장률
%
Diagram 주요 시장 플레이어
  • AB Science (France)
  • Elanco (U.S.)
  • Candel Therapeutics (Canada)
  • NIPPON ZENYAKU KOGYO CO. LTD. (Japan)
  • Rhizen Pharmaceuticals AG (Switzerland)

Global Pet Cancer Therapeutics Market, By Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Combination Therapy, and Others), Medicine Type (Chemotherapy Drugs and Vaccines), Route of Administration (Parenteral, Oral, and Others), Cancer Type (Melanoma, Mast Cell Cancer, Lymphoma, Mammary and Squamous Cell Cancer, and Others), Species Type (Cat, Dog, and Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2031.

Pet Cancer Therapeutics Market

Pet Cancer Therapeutics Market Analysis and Size

The pet cancer therapeutics market is advancing rapidly with the latest methods and technologies driving growth. Innovations such as targeted therapies and immunotherapy are transforming treatment approaches. Rising pet healthcare expenditures and increasing pet longevity contribute to market expansion. Companies are focusing on precision medicine and personalized treatments, enhancing efficacy and outcomes in managing cancer in pets.

The global pet cancer therapeutics market size was valued at USD 283.86 million in 2023 and is projected to reach USD 569.77 million by 2031, with a CAGR of 9.10% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Combination Therapy, and Others), Medicine Type (Chemotherapy Drugs and Vaccines), Route of Administration (Parenteral, Oral, and Others), Cancer Type (Melanoma, Mast Cell Cancer, Lymphoma, Mammary and Squamous Cell Cancer, and Others), Species Type (Cat, Dog, and Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

AB Science (France), Elanco (U.S.), Candel Therapeutics (Canada), NIPPON ZENYAKU KOGYO CO., LTD. (Japan), Rhizen Pharmaceuticals AG (Switzerland), Virbac Corporation (France), Pfizer Inc. (U.S.), VetDC (U.S.), Boehringer Ingelheim International GmbH (Germany), Karyopharm (U.S.), VETCO (U.S.), ELIAS Animal Health (U.S.), Vivesto AB (Sweden), Torigen Pharmaceuticals Inc. (U.S.), and Zoetis Services LLC (U.S.)

Market Opportunities

  • Regulatory Support and Guidelines
  • Improved Diagnostic Capabilities

Market Definition

Pet cancer therapeutics refer to treatments and medications designed to diagnose, manage, and potentially cure cancer in animals. These therapies include chemotherapy, surgery, radiation, and targeted therapies tailored to specific types of cancer in pets. The goal is to improve quality of life, extend survival, and minimize pain and discomfort associated with cancer in dogs, cats, and other companion animals.            

Pet Cancer Therapeutics Market Dynamics

Drivers

  • Increasing Pet Ownership

Increasing pet ownership globally has led to heightened awareness and increased spending on pet healthcare, significantly boosting demand for advanced therapies in the pet cancer therapeutics market. For instance, as more households treat pets as family members, there's a greater willingness to invest in treatments such as cancer therapies, driving market growth. This trend is supported by a growing number of veterinary clinics offering specialized oncology services tailored to meet the needs of pet owners seeking advanced healthcare options.

  • Advancements in Veterinary Medicine

Advancements in veterinary medicine, particularly in oncology, are driving growth in the pet cancer therapeutics market. For instance, new treatment modalities such as targeted therapies and immunotherapies offer more effective and less invasive options for treating cancer in pets. Additionally, advanced diagnostic technologies such as molecular imaging and genetic testing enable earlier detection and personalized pet cancer treatment approaches, improving outcomes and fostering higher demand for specialized veterinary oncology services and products.

Opportunities

  • Regulatory Support and Guidelines

Clearer regulatory frameworks and guidelines are pivotal in driving the pet cancer therapeutics market by ensuring safer and more effective treatments. For instance, the FDA's Center for Veterinary Medicine (CVM) provides guidance on drug approval processes, ensuring products meet safety and efficacy standards. Such frameworks encourage investment in research and development, fostering innovation in treatments tailored to pets' specific cancer types, ultimately expanding treatment options and improving outcomes for companion animals.

  • Improved Diagnostic Capabilities

Improved diagnostic capabilities in veterinary oncology have significantly enhanced early detection and treatment planning for pet cancers. Advanced imaging techniques such as CT scans and MRI, alongside genetic testing for biomarker identification, allow veterinarians to diagnose cancers earlier and tailor treatments more effectively. For instance, the use of next-generation sequencing helps identify specific mutations in tumors, guiding targeted therapies. This capability not only improves outcomes but also drives growth in the pet cancer therapeutics market by promoting timely and personalized treatment strategies. 

Restraints/Challenges

  • High Cost of Treatment

The high cost of cancer treatment for pets acts as a significant barrier, restricting access for many owners and thereby hindering market growth. The expense involved often deters potential customers from pursuing such treatments, impacting market expansion negatively. This financial constraint limits the market's potential reach and adoption among pet owners, creating a substantial hurdle for companies operating in the pet cancer therapeutics sector. 

  • Complexity of Treatment

Administering and monitoring cancer treatments in pets poses significant challenges due to their diverse physiology and behavioral variations. This complexity hinders market growth by complicating treatment efficacy and consistency. Veterinarians face difficulties in standardizing care across different animal species and breeds, impacting treatment outcomes. These inherent differences contribute to the overall complexity and unpredictability of managing cancer therapies in pets, creating barriers to market expansion. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In July 2022, Fort Wayne Animal Care and Control received a USD 35,000 grant from Petco Love to bolster their efforts in saving animal lives in Fort Wayne. This funding aims to enhance their capacity for animal welfare initiatives, including adoption programs and veterinary care
  • In June 2022, Petco Love allocated USD 75,000 grant to Cornell University College of Veterinary Medicine. This long-standing partnership supports subsidized cancer treatments for dogs and cats, advancing veterinary oncology research and care
  • In June 2022, Boehringer Ingelheim and CarthroniX embarked on a collaboration to innovate canine oncology. They aim to pioneer novel small molecule therapies for aging-related and degenerative diseases in dogs, potentially expanding Boehringer Ingelheim's Animal Health portfolio

Pet Cancer Therapeutics Market Scope

The market is segmented on the basis of therapy, medicine type, route of administration, cancer type, species type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Combination Therapy
  • Others

 Medicine Type

 Route of Administration

  • Parenteral
  • Oral
  • Others

 Cancer Type

  • Melanoma
  • Mast Cell Cancer
  • Lymphoma
  • Mammary and Squamous Cell Cancer
  • Others

 Species Type

  • Cat
  • Dog
  • Others

 End User

  • Veterinary Hospitals and Clinical Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Pet Cancer Therapeutics Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, therapy, medicine type, route of administration, cancer type, species type and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the pet cancer therapeutics market due to rising prevalence, robust healthcare infrastructure, and significant research investments. These factors contribute to its leading position in advancing treatments for pets diagnosed with cancer.

Asia-Pacific is expected to expand at a significant growth in the pet cancer therapeutics market due to increasing incidence, awareness, government initiatives, and disposable incomes in the region, fostering market expansion over the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Pet Cancer Therapeutics Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

  • AB Science (France)
  • Elanco (U.S.)
  • Candel Therapeutics (Canada)
  • NIPPON ZENYAKU KOGYO CO., LTD. (Japan)
  • Rhizen Pharmaceuticals AG (Switzerland)
  •  Virbac Corporation (France)
  • Pfizer Inc. (U.S.)
  • VetDC (U.S.)
  • Boehringer Ingelheim International GmbH (Germany)
  • Karyopharm (U.S.)
  • VETCO (U.S.)
  • ELIAS Animal Health (U.S.)
  • Vivesto AB (Sweden)
  • Torigen Pharmaceuticals Inc. (U.S.)
  • Zoetis Services LLC (U.S.)


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The market is segmented based on , By Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Combination Therapy, and Others), Medicine Type (Chemotherapy Drugs and Vaccines), Route of Administration (Parenteral, Oral, and Others), Cancer Type (Melanoma, Mast Cell Cancer, Lymphoma, Mammary and Squamous Cell Cancer, and Others), Species Type (Cat, Dog, and Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2031. .
The Global Pet Cancer Therapeutics Market size was valued at USD 283.86 USD Million in 2023.
The Global Pet Cancer Therapeutics Market is projected to grow at a CAGR of 9.1% during the forecast period of 2024 to 2031.
The major players operating in the market include AB Science (France), Elanco (U.S.), Candel Therapeutics (Canada), NIPPON ZENYAKU KOGYO CO. LTD. (Japan), Rhizen Pharmaceuticals AG (Switzerland), Virbac Corporation (France), Pfizer Inc. (U.S.), VetDC (U.S.), Boehringer Ingelheim International GmbH (Germany), Karyopharm (U.S.), VETCO (U.S.), ELIAS Animal Health (U.S.), Vivesto AB (Sweden), Torigen Pharmaceuticals Inc. (U.S.), and Zoetis Services LLC (U.S.).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..